On February 5, 2021, the FDA approved Juno Therapeutics, Inc.’s Breyanzi® (lisocabtagene maraleucel) for “treatment of adult patients with relapsed or refractory large B-cell lymphoma.” Juno, a Bristol-Myers Squibb Company, was authorized to manufacture Breyanzi at its Bothell, Washington facility and provide it to patients under a risk evaluation and mitigation strategy (REMS). Breyanzi was designated as an orphan drug on April 1, 2020 and will be manufactured separately for each individual patient.
- How-to guide How-to guide: How to avoid liability for defective products in supply of goods agreements (USA)
- How-to guide How-to guide: How to negotiate and draft governing law and court jurisdiction clauses in a commercial agreement (UK)
- Checklist Checklist: When and how to appoint a data protection officer (UK)